Storia in 4 fonti

Alnylam cuts Amvuttra sales guidance as demand shifts, hurting stock

Alnylam cuts Amvuttra sales forecast ~$200M after misjudging market demand; stock drops premarket.

Raccontata da

Confronto fonti

4 prospettive sulla stessa storia

AI · summaries

benzinga.com2 g fa

Alnylam Lowers 2026 Outlook As Second-Line Amvuttra Demand Normalizes, Stock Tanks - Alnylam Pharmaceutic

Alnylam cut 2026 guidance ($5.275-5.725B) as Amvuttra second-line demand normalized. Stock fell 29%. Ionis trial failure in ATTR-CM gene-silencing raises efficacy concerns; Alnylam's Nucresiran Phase 3 faces program risk, signaling broader biotech R&D portfolio pressure.

Leggi questa versione → originale

fiercepharma.com2 g fa

Alnylam shares tank 29% as Amvuttra disappoints with ATTR outlook cut for 2026

Alnylam's Amvuttra missed Q2 targets ($1.01B vs $1.05B expected), sparking a 29% stock drop and a $200M guidance cut. Competitive moats are widening as AstraZeneca's rival failed trials, but execution risk persists in reaching first-line market share targets.

Leggi questa versione →

Timeline cronologica

martedì 28 luglio 2026·endpoints.news
Alnylam's stock is down 30% despite a booming biotech market. Here's why.
Alnylam's stock is down 30% in 2026 despite Amvuttra's success. Wainua's Phase 3 failure raised doubts about RNAi silencers like Amvuttra and nucresiran. Q2 earnings due July 30.
giovedì 30 luglio 2026·biopharmadive.com
Alnylam plunges as earnings deliver ‘one-two punch’
The RNA-focused biotech shed 30% of its market value — or close to $12 billion — amid growing investor concerns about its main drug business.

Alnylam Lowers 2026 Outlook As Second-Line Amvuttra Demand Normalizes, Stock Tanks - Alnylam Pharmaceutic

Alnylam shares tank 29% as Amvuttra disappoints with ATTR outlook cut for 2026

Timeline cronologica

Alnylam's stock is down 30% despite a booming biotech market. Here's why.

Alnylam plunges as earnings deliver ‘one-two punch’

Alnylam's stock is down 30% despite a booming biotech market. Here's why.

Alnylam plunges as earnings deliver ‘one-two punch’